Editorial Board member, Ulka Vaishampayan, talks to us at the ASCO 2019 annual meeting about recent advances in prostate and kidney cancer. Discussing the rationale for apalutamide addition in metastatic castration-sensitive prostate cancer alongside the findings from the TITAN study (NCT02489318) she highlights the impact these results will have on clinical practice. Further data presented from the CARMENA trial (NCT00930033) at the meeting are also discussed alongside how the overall study has affected the management of metastatic renal cell carcinoma.
1. What is the rationale for the addition of apalutamide to androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer? (0:04)
2. What were the major efficacy and safety findings of the TITAN study? (0:36)
3. What impact will these findings have on clinical practice? (1:36)
4. How have the findings of the CARMENA trial affected the role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma (RCC)? (2:41)
5.Could you tell us about the update on the CARMENA trial in the intermediate IMDC-risk population? (4:18)
Speaker disclosure: Ulka Vaishampaya has received honoraria and acted as a consultant for Pfizer, Bayer, Exelixis, BMS and Eisai. She has also received research support from BMS, Amgen, Exelixis and Astellas.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Genitourinary Cancers
Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder
touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]
Joaquim Bellmunt, ASCO 2021: 5-year Follow-up from the Phase 3 KEYNOTE-045 Trial
touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial […]
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!